Results 61 to 70 of about 5,926 (192)
A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics
Andrology, EarlyView.ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis +3 more
wiley +1 more source
Drug Design, Development and Therapy, 2020 Mohamed W Attwa, 1, 2 Adnan A Kadi, 1 Ali S Abdelhameed, 1 Hassan A Alhazmi 3, 4 1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; 2Students’ University Hospital, Mansoura University ...
Attwa MW +3 more
doaj
Медицинский совет, 2020 Introduction. The presence of a germinal BRCA mutation occurs in 3–4% of all breast cancer (BC) patients with various biological subtypes, but significantly with a high frequency in patients with a triple negative biological subtype (in 10–20% of cases).
T. Yu. Semiglazova +22 more
doaj +1 more source
Evidence to date: talazoparib in the treatment of breast cancer.
OncoTargets and therapy, 2019 Approximately 5-10% of all patients diagnosed with breast cancer have germline BRCA1/2 mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recently approved for use in patients with metastatic breast
Exman,Pedro +2 more
openaire +3 more sources
Advances in the use of PARP inhibitor therapy for breast cancer
Drugs in Context, 2018 Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described.
Kelly E McCann, Sara A Hurvitz
doaj +1 more source
PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines
FEBS Open Bio, Volume 16, Issue 7, Page 1370-1386, July 2026.Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart +7 more
wiley +1 more source
, 2017 Prostate cancer is the most common cancer among men, other than skin cancer, in the United States. When the cancer enters into the metastatic castration resistant stage (mCRPC), few treatment options are currently available and the disease is considered ...
Zachary Z. Reinstein +5 more
core +1 more source
Molecular Oncology, Volume 20, Issue 6, Page 1626-1642, June 2026.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Abstract P5-06-01: Talazoparib antitumor effects in BRCA-deficient breast cancer models
, 2017 Background: BRCA1 and BRCA2 functions are essential for the DNA double-strand break repair process in living cells with DNA damages. Therefore, germline pathogenic mutations in BRCA1/2 increases the risk of developing cancer.1, 2Poly(ADP-ribose ...
VT Phan, AA Protter, H Uppal, A Peterson
core +1 more source
Frontiers in Oncology, 2021 Renal cell carcinoma (RCC) is the sixth most common cancer in the US. However, no significant changes in management have occurred since the tyrosine kinase era until the recent breakthrough with checkpoint inhibitors.
Jerred P. Pletcher +11 more
doaj +1 more source